Barts & The London NHS Trust   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: London United Kingdom (2012)

Organization Overview

First Clinical Trial
2012
NCT00003014
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Barts and the London School of Medicine and Dentistry | Barts Charity | Barts Health NHS Trust | Barts Health NHS Trust, London, United Kingdom (NSMP-ORANGE trial) | Barts Health NHS Trust; Queen Mary University London | Barts Heart Centre | Barts & The London NHS Trust | Centre for Experimental Cancer Medicine (CECM), Barts Cancer Institute | Centre for Health Sciences, Barts and The London, QMUL | Centre for Health Sciences, Queen Mary's School of Medicine and Dentistry | Department ofRespiratory Medicine, London Chest Hospital, Barts& The London NHS Trust,Bonner Road, E2 9JX, London (UK) | Homerton University Hospital | Pain and Anaesthesia Research Centre, Barts Health NHS Trust | Queen Mary's School of Medicine & Dentistry, London (UK) | Queen Mary's School of Medicine & Dentistry, London, UK | Southampton NCRI/CR UK Experimental Cancer Medicines Centre | St. Bartholomew's Hospital | St Bartholomew's Hospital, London, UK | Translational Medicine & Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London

Active Ingredients

Drugs in Phase 4 Trials (13)

acetaminophen (tylenol) (2 trials)

beclomethasone (vanceril) (1 trial)

ergocalciferol (drisdol) (2 trials)

fluticasone (cutivate) (2 trials)

formoterol (foradil) (1 trial)

glycopyrronium (robinul) (1 trial)

ketamine (ketalar) (1 trial)

lidocaine (xylocaine) (1 trial)

meperidine (demerol) (1 trial)

methylprednisolone (medrol) (1 trial)

pregabalin (lyrica) (1 trial)

remifentanil (ultiva) (1 trial)

sodium chloride (2 trials)

Drugs in Phase 3 Trials (30)

acetylsalicylic acid (aspirin) (1 trial)

bleomycin (blenoxane) (2 trials)

capivasertib (1 trial)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (3 trials)

cyproviron (1 trial)

darbepoetin alfa (aranesp) (2 trials)

darbepoetin beta (1 trial)

diethylstilbestrol (Fosfestrol) (1 trial)

diindolylmethane (1 trial)

enoxaparin (lovenox) (1 trial)

epoetin (Epogen) (1 trial)

etoposide (vepesid) (1 trial)

gonadorelin (factrel) (1 trial)

iron dextran (Imferon) (1 trial)

melphalan (alkeran) (1 trial)

miglitol (glyset) (1 trial)

miglyol oil (3 trials)

ondansetron (zofran) (1 trial)

paclitaxel (taxol) (4 trials)

potassium (1 trial)

red blood cells (1 trial)

rivaroxaban (xarelto) (1 trial)

sargramostim (leukine) (5 trials)

semuloparin (1 trial)

sitagliptin (januvia) (1 trial)

sucroferric oxyhydroxide (Venofer) (1 trial)

urea (2 trials)

vitamin d3 (3 trials)

warfarin (coumadin) (1 trial)

Drugs in Phase 2 Trials (27)

aflibercept (zaltrap) (1 trial)

allogeneic bone marrow (1 trial)

azd1656 (1 trial)

berotralstat (Orladeyo) (1 trial)

bone marrow derived mononuclear cells (1 trial)

bortezomib (velcade) (2 trials)

ccs1477 (1 trial)

Cetilistat (oblean) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dactinomycin (cosmegen) (1 trial)

Filgrastim (neupogen) (1 trial)

fludarabine (fludara) (1 trial)

gemcitabine (gemzar) (2 trials)

naltrexone (revia) (1 trial)

orlistat (xenical) (1 trial)

oxaliplatin (eloxatin) (1 trial)

panobinostat (farydak) (1 trial)

paricalcitol (zemplar) (1 trial)

pegylated arginine deiminase (2 trials)

potassium chloride (klor-con) (1 trial)

potassium nitrate (1 trial)

rituximab (rituxan) (1 trial)

sodium nitrite (1 trial)

sunitinib (sutent) (1 trial)

thalidomide (Thalomid) (1 trial)

tranexamic acid (cyklokapron) (1 trial)

zirconium silicate (Lokelma) (1 trial)

Drugs in Phase 1 Trials (3)

99mtc demobesin-4 (1 trial)

kw-2478 (1 trial)

tretinoin (Retin-A) (1 trial)

Drugs in Other Trials (11)

beetroot juice (1 trial)

chlorambucil (Leukeran) (1 trial)

dacarbazine (dtic-dome) (1 trial)

doxorubicin (Doxil) (1 trial)

furosemide (lasix) (1 trial)

ketone monoester (1 trial)

prednisone (meticorten) (1 trial)

procarbazine (matulane) (1 trial)

tacrolimus (prograf) (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

ACTH-Secreting Pituitary Adenoma (Phase 3)

Acute Coronary Syndrome (Phase 2)

Acute Kidney Injury (Phase 2)

Adenocarcinoma (Phase 2)

Anemia (Phase 3)

Angioedema (Phase 2)

Angioedemas, Hereditary (Phase 2)

Antiphospholipid Syndrome (Phase 3)

Arrhythmias, Cardiac (Phase 3)

Asthma (Phase 4)

Breast Neoplasms (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Cardiomyopathies (Phase 2)

Cardiomyopathy, Dilated (Phase 2)

Cardiovascular Diseases (Phase 2)

Chronic Disease (Phase 4)

Colorectal Neoplasms (Phase 2)

Communicable Diseases (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diarrhea (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Headache (Phase 4)

Heart Failure (Phase 3)

Hematologic Neoplasms (Phase 2)

Hemorrhage (Phase 2)

Hyperalgesia (Phase 4)

Infarction (Phase 2)

Infections (Phase 3)

Influenza, Human (Phase 3)

Irritable Bowel Syndrome (Phase 3)

Ischemia (Phase 3)

Kidney Diseases (Phase 4)

Kidney Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lung Diseases (Phase 4)

Lung Diseases, Obstructive (Phase 4)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Mesothelioma (Phase 2)

Migraine Disorders (Phase 4)

Multiple Myeloma (Phase 3)

Myelodysplastic Syndromes (Phase 3)

Myocardial Infarction (Phase 2)

Myocardial Ischemia (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Neuralgia (Phase 4)

Pituitary ACTH Hypersecretion (Phase 3)

Plasmacytoma (Phase 3)

Precancerous Conditions (Phase 3)

Preleukemia (Phase 3)

Prostatic Neoplasms (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Reperfusion Injury (Phase 2)

Respiratory Tract Infections (Phase 3)

Seminoma (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Syndrome (Phase 3)

Thromboembolism (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Tuberculosis (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Venous Thromboembolism (Phase 3)

Vitamin D Deficiency (Phase 4)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 58
  • # of Trial APIs: 84